Masimo (MASI) 44th Annual J.P. Morgan Healthcare Conference summary

Business performance and financial highlights

• Achieved over $1.5 billion in revenue, 9%+ annual growth, and 11%+ quarterly growth in Q4, with 500 basis points margin expansion and 30%+ EPS growth in the past year.

• 80%+ recurring revenue and 99%+ renewal rate, with a resilient supply chain and strong engineering retention.

• Guidance met or exceeded for revenue and earnings, expecting to close the year at the high end of guidance.

• Long-range plan targets 7%-10% annual growth and 30% operating margin by 2028, with EPS approaching $8.

• Strong cash flow and share buybacks, with natural leverage expected to drive future profitability.

Strategic focus and growth drivers

• Growth strategy centers on U.S. pulse oximetry (40% of growth), international expansion (20%), advanced monitoring (one-third), and new product launches.

• U.S. pulse ox market share at 55%, growing 1-2 points per year; international share at 35% in a faster-growing $800M market.

• Advanced monitoring market share at 10%-15%, with double-digit growth potential.

• Continuous monitoring seen as a $2B market opportunity, pending regulatory and technological advances.

• Focused on commercial excellence, innovation, and expanding in Japan and Asia-Pacific, where significant growth potential exists.

Innovation, product pipeline, and AI integration

• New product launches planned in every major category, including next-gen monitors and wearables.

• AI and algorithm development are core strengths, with a dedicated team and a pipeline including AFib detection, opioid-induced respiratory depression, and predictive analytics.

• Radius VSM, a wearable vital signs monitor, moving from pilot to full launch; next-gen Root monitors to launch by end of 2027.

• Smart sensors for opioid-induced respiratory depression and AFib detection submitted to FDA, with launches expected in 2026.

• Wearable strategy being developed for continuous hospital monitoring, with multiple FDA-cleared devices already in portfolio.